Acadian Asset Management
SCPH

Acadian Asset Management’s scPharmaceuticals SCPH Stock Holding History

Acadian Asset Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,060
Closed -$41K – 2097
2024
Q3 		$41K Buy
+9,060
New +$43.8K ﹤0.01% 1856
2020
Q4 		– Sell
-9,547
Closed -$72K – 2338
2020
Q3 		$72K Sell
9,547
-5,208
-35% -$40.7K ﹤0.01% 1756
2020
Q2 		$108K Buy
14,755
+4,408
+43% +$38.7K ﹤0.01% 1699
2020
Q1 		$76K Buy
10,347
+1,463
+16% +$10.6K ﹤0.01% 1411
2019
Q4 		$51K Hold
8,884
– – ﹤0.01% 1596
2019
Q3 		$53K Buy
8,884
+4,361
+96% +$24.6K ﹤0.01% 1604
2019
Q2 		$14K Buy
+4,523
New +$14.8K ﹤0.01% 1622
2019
Q1 		– Sell
-34,841
Closed -$131K – 2033
2018
Q4 		$131K Hold
34,841
– – ﹤0.01% 1210
2018
Q3 		$205K Buy
34,841
+5,026
+17% +$25.6K ﹤0.01% 1074
2018
Q2 		$169K Buy
+29,815
New +$306K ﹤0.01% 1130

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Acadian Asset Management's SCPH Position: Q4 2024 in Review

Acadian Asset Management sold out of scPharmaceuticals (SCPH) in Q4 2024, closing a stake of 9,060 shares — an estimated $41K sold.

Acadian Asset Management first reported a position in SCPH in Q2 2018 and held it in 10 quarters. The position peaked at $205K in Q3 2018. 85 funds tracked by Wall St. Rank hold SCPH as of Q4 2024.

  • Acadian Asset Management reported no remaining scPharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 9,060 scPharmaceuticals shares in Q4 2024, an estimated $41K.
  • Acadian Asset Management first reported a position in scPharmaceuticals in Q2 2018 and held it in 10 quarters.
  • Acadian Asset Management's scPharmaceuticals position peaked at $205K in Q3 2018.
  • 85 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.